"We're seeing that it's beneficial to the patient—it’s easier, they don't require a general anesthetic, and we don't have to bring him to the hospital," says Dr. Hafron.
During the 2022 LUGPA Annual Meeting, Jason Hafron, MD, sat down with Urology Times® to discuss how his use of Jelmyto has evolved since the low-grade upper tract urothelial carcinoma treatment was approved in April 2020. Dr. Hafron is the Chief Medical Officer and Director of Clinical Research at the Michigan Institute of Urology and a professor of urology at Oakland University.
Blue light cystoscopy decreases risk of recurrence, progression in NMIBC
May 9th 2024“The results of the BRAVO study performed within the VA health care system showed significant decreases in the risk of recurrence and progression, as well as the potential for improved overall survival in patients who received a BLC compared to patients who received WLC only,” says Stephen B. Williams, MD, MBA, MS, FACS, FACHE.